855 related articles for article (PubMed ID: 2548711)
1. Antigenic profile of tumor progression stages in human melanocytic nevi and melanomas.
Elder DE; Rodeck U; Thurin J; Cardillo F; Clark WH; Stewart R; Herlyn M
Cancer Res; 1989 Sep; 49(18):5091-6. PubMed ID: 2548711
[TBL] [Abstract][Full Text] [Related]
2. Characteristics of cultured human melanocytes isolated from different stages of tumor progression.
Herlyn M; Thurin J; Balaban G; Bennicelli JL; Herlyn D; Elder DE; Bondi E; Guerry D; Nowell P; Clark WH
Cancer Res; 1985 Nov; 45(11 Pt 2):5670-6. PubMed ID: 4053039
[TBL] [Abstract][Full Text] [Related]
3. The differential reactivity of cells of the melanocytic lineage with four monoclonal antibodies against IFN-gamma inducible molecules.
Vacca A; Frassanito A; Rimoldi D; Dammacco F; Carrel S
Anticancer Res; 1992; 12(1):1-9. PubMed ID: 1348919
[TBL] [Abstract][Full Text] [Related]
4. Interferon-gamma regulates the T cell response to precursor nevi and biologically early melanoma.
Guerry D; Alexander MA; Elder DE; Herlyn MF
J Immunol; 1987 Jul; 139(1):305-12. PubMed ID: 3108402
[TBL] [Abstract][Full Text] [Related]
5. Tumor progression in the human melanocytic system.
Kath R; Rodeck U; Menssen HD; Mancianti ML; Linnenbach AJ; Elder DE; Herlyn M
Anticancer Res; 1989; 9(4):865-72. PubMed ID: 2554787
[TBL] [Abstract][Full Text] [Related]
6. The initial steps of tumor progression in melanocytic lineage: a histochemical approach.
Wollina U; Kilian U; Henkel U; Schaarschmidt H; Knopf B
Anticancer Res; 1991; 11(4):1405-14. PubMed ID: 1746897
[TBL] [Abstract][Full Text] [Related]
7. Surface antigens of melanomas and melanocytes defined by mouse monoclonal antibodies: specificity analysis and comparison of antigen expression in cultured cells and tissues.
Real FX; Houghton AN; Albino AP; Cordon-Cardo C; Melamed MR; Oettgen HF; Old LJ
Cancer Res; 1985 Sep; 45(9):4401-11. PubMed ID: 4028024
[TBL] [Abstract][Full Text] [Related]
8. Surface antigenic profile of uveal melanoma lesions analysed with a panel of monoclonal antibodies directed against cutaneous melanoma.
Carrel S; Schreyer M; Gross N; Zografos L
Anticancer Res; 1990; 10(1):81-9. PubMed ID: 1692197
[TBL] [Abstract][Full Text] [Related]
9. Selective monomorphic and polymorphic HLA class I antigenic determinant loss in surgically removed melanoma lesions.
Kageshita T; Ishihara T; Campoli M; Ferrone S
Tissue Antigens; 2005 May; 65(5):419-28. PubMed ID: 15853896
[TBL] [Abstract][Full Text] [Related]
10. Recombinant gamma-interferon induces changes in expression and shedding of antigens associated with normal human melanocytes, nevus cells, and primary and metastatic melanoma cells.
Herlyn M; Guerry D; Koprowski H
J Immunol; 1985 Jun; 134(6):4226-30. PubMed ID: 2985706
[TBL] [Abstract][Full Text] [Related]
11. Immunohistological characterisation of tumour infiltrating lymphocytes in melanocytic skin lesions.
Hussein MR; Elsers DA; Fadel SA; Omar AE
J Clin Pathol; 2006 Mar; 59(3):316-24. PubMed ID: 16505286
[TBL] [Abstract][Full Text] [Related]
12. A new Mr 55,000 surface protein implicated in melanoma progression: association with a metastatic phenotype.
Boukerche H; Baril P; Tabone E; Bérard F; Sanhadji K; Balme B; Wolf F; Perrot H; Thomas L
Cancer Res; 2000 Oct; 60(20):5848-56. PubMed ID: 11059782
[TBL] [Abstract][Full Text] [Related]
13. Tumor progression in melanoma: the biology of epidermal melanocytes in vitro.
Mancianti ML; Herlyn M
Carcinog Compr Surv; 1989; 11():369-86. PubMed ID: 2646021
[TBL] [Abstract][Full Text] [Related]
14. Biology of tumor progression in human melanocytes.
Herlyn M; Clark WH; Rodeck U; Mancianti ML; Jambrosic J; Koprowski H
Lab Invest; 1987 May; 56(5):461-74. PubMed ID: 3553733
[TBL] [Abstract][Full Text] [Related]
15. Differential expression of melanoma associated antigens in acral lentiginous melanoma and in nodular melanoma lesions.
Kageshita T; Nakamura T; Yamada M; Kuriya N; Arao T; Ferrone S
Cancer Res; 1991 Mar; 51(6):1726-32. PubMed ID: 1671829
[TBL] [Abstract][Full Text] [Related]
16. Immunohistochemical analysis of malignant melanomas and nevocellular nevi with monoclonal antibodies to distinct monomorphic determinants of HLA antigens.
Ruiter DJ; Bergman W; Welvaart K; Scheffer E; van Vloten WA; Russo C; Ferrone S
Cancer Res; 1984 Sep; 44(9):3930-5. PubMed ID: 6204749
[TBL] [Abstract][Full Text] [Related]
17. Antigenic profiles of individual-matched pairs of primary and melanoma metastases.
Meije CB; Swart GW; Lepoole C; Das PK; Van den Oord JJ
Hum Pathol; 2009 Oct; 40(10):1399-407. PubMed ID: 19386352
[TBL] [Abstract][Full Text] [Related]
18. Adhesion molecule profile and malignancy of melanocytic lesions.
Moretti S; Martini L; Berti E; Pinzi C; Giannotti B
Melanoma Res; 1993 Aug; 3(4):235-9. PubMed ID: 8219755
[TBL] [Abstract][Full Text] [Related]
19. Association between sialyl Lewis(a) expression and tumor progression in melanoma.
Kageshita T; Hirai S; Kimura T; Hanai N; Ohta S; Ono T
Cancer Res; 1995 Apr; 55(8):1748-51. PubMed ID: 7712483
[TBL] [Abstract][Full Text] [Related]
20. Diagnostic assessment of two novel proliferation-specific antigens in benign and malignant melanocytic lesions.
Rudolph P; Lappe T; Schubert C; Schmidt D; Parwaresch RM; Christophers E
Am J Pathol; 1995 Dec; 147(6):1615-25. PubMed ID: 7495287
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
